FIELD: medicine.
SUBSTANCE: invention relates to the use of a compound of the formula (I), its tautomers or pharmaceutically acceptable salts for the prevention of hepatocellular carcinoma (HCC) induced by non-alcoholic steatohepatitis (hereinafter – NASH) in a subject.
EFFECT: prevention of NASH-induced hepatocellular carcinoma in a subject.
1 cl, 3 dwg, 2 ex
| Title |
Year |
Author |
Number |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE |
2019 |
- Li, Chian Dzh.
- Derdak, Zoltan
- Lyu, Tszifen
|
RU2815647C2 |
| NEW APPLICATIONS AND METHODS |
2017 |
- Fansa-Berton, Paskal Elizabet Rene
- Falkao, Lejla Deniz
- Bili, Antuan Sharl
- Roller, Mark
- Birtik, Simona
|
RU2765804C2 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE |
2017 |
- Wu, Edwin, Sc
- Chiu, Peter, J.S.
- Hsu, May, Mei-Chi
|
RU2717677C1 |
| COMPOSITION USED TO COMBAT METABOLIC DISEASES AND USE OF COMPOSITION |
2020 |
- Ng, Shyh Chang
- Ma, Shi Lin
|
RU2827553C1 |
| TREATMENT OF LIVER, BILE DUCT AND PANCREATIC DISORDERS |
2017 |
- Nordkild, Peter
- Kjaerulff, Soren
|
RU2740913C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS |
2008 |
- Dokhil Randzhan
- Shnajder Dzherri
|
RU2498795C2 |
| COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT |
2015 |
|
RU2723559C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER |
2017 |
- Ohtani Naoko
- Kamachi Fumitaka
- Loo Tze Mun
- Koizumi Shinichi
- Okumura Takako
|
RU2717331C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER |
2017 |
- Ohtani, Naoko
- Kamachi, Fumitaka
- Loo, Tze Mun
- Koizumi, Shinichi
- Okumura, Takako
|
RU2762193C2 |
| BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND RELATED METABOLIC DISORDERS |
2016 |
- Kiely Barry
- Murphy Eileen Frances
- Healy Selena
|
RU2740096C2 |
